Acalabrutinib: all 124 studies that test it
Page 1 of 2. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.
- Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruitingNCT07635511Phase 3
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNot yet recruitingNCT07582159Phase 2
- MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingNCT07024706Phase 2
- Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLRecruitingNCT07014917Phase 2
- Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaRecruitingNCT06846489Phase 2
- Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT06757647Phase 2
- Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureRecruitingNCT06651970Phase 4
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
- A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)RecruitingNCT06428019Phase 3
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingNCT06319456Phase 3
- Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06054776Phase 2
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingNCT05952024Phase 2
- A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLLRecruitingNCT05950997Not applicable
- Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT05943496Phase 1
- Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell LymphomaRecruitingNCT05820841Phase 3
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell LymphomaRecruitingNCT05256641Phase 1/2
- A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLRecruitingNCT05197192Phase 3
- Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialRecruitingNCT04941716Phase 2
- Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasRecruitingNCT04883437Phase 2
- Avo In R/R And Previously Untreated MCLRecruitingNCT04855695Phase 1/2
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingNCT04404088Phase 2
- Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT04169737Phase 2
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingNCT04002947Phase 2
- Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early TreatmentRecruitingNCT03868722Phase 2/3
- A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLRecruitingNCT03571568Phase 1/2
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT03516617Phase 2
- Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell LymphomasActive, not recruitingNCT05583149Phase 2Results posted
- Preventing Anaphylaxis With AcalabrutinibCompletedNCT05038904Phase 2Results posted
- Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaCompletedNCT04930536Phase 4Results posted
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04783415Phase 2Results posted
- Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT04657094Phase 2Results posted
- Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell LymphomaActive, not recruitingNCT04626791Phase 2Results posted
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingNCT04624633Phase 2Results posted
- A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS LymphomasActive, not recruitingNCT04548648Phase 2Results posted
- Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19TerminatedNCT04497948Phase 1Results posted
- Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell LymphomaCompletedNCT04402138Phase 2Results posted
- Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.CompletedNCT04380688Phase 2Results posted
- Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.CompletedNCT04346199Phase 2Results posted
- Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative DisorderTerminatedNCT04337827Phase 2Results posted
- Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaActive, not recruitingNCT04257578Phase 1/2Results posted
- Acalabrutinib for the Treatment of Chronic Graft Versus Host DiseaseActive, not recruitingNCT04198922Phase 2Results posted
- Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaTerminatedNCT04189952Phase 2Results posted
- Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT04075292Phase 3Results posted
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedNCT04016805Phase 2Results posted
- Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsCompletedNCT04008706Phase 3Results posted
- Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its MetaboliteCompletedNCT03968848Phase 1Results posted
- Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell MalignanciesActive, not recruitingNCT03932331Phase 1/2Results posted
- Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaCompletedNCT03788291Phase 2Results posted
- Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaCompletedNCT03623373Phase 2Results posted
- Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLActive, not recruitingNCT03580928Phase 2Results posted
- A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell MalignanciesTerminatedNCT03205046Phase 1/2Results posted
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLActive, not recruitingNCT02970318Phase 3Results posted
- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyActive, not recruitingNCT02717611Phase 2Results posted
- A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)Active, not recruitingNCT02586857Phase 1/2Results posted
- Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic CancerTerminatedNCT02570711Phase 2Results posted
- Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)CompletedNCT02537444Phase 2Results posted
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT02477696Phase 3Results posted
- Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLActive, not recruitingNCT02475681Phase 3Results posted
- Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT02454179Phase 2Results posted
- Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT02448303Phase 2Results posted
- ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background MethotrexateCompletedNCT02387762Phase 2Results posted
- ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic CancerCompletedNCT02362048Phase 2Results posted
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
- Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLCompletedNCT02337829Phase 2Results posted
- Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell MalignanciesCompletedNCT02328014Phase 1/2Results posted
- An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaActive, not recruitingNCT02213926Phase 2Results posted
- An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02211014Phase 1Results posted
- An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaActive, not recruitingNCT02180724Phase 2Results posted
- Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaCompletedNCT02112526Phase 1Results posted
- ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic LeukemiaActive, not recruitingNCT02029443Phase 1/2Results posted
- A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawnNCT06839872Phase 2
- Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaActive, not recruitingNCT05971251Phase 1
- A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
- A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaActive, not recruitingNCT05495464Early Phase 1
- Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05388006Phase 2
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
- ACALA-R In Predominantly Demyelinating IgM Mediated NeuropathyActive, not recruitingNCT05065554Phase 2
- A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05057494Phase 3
- Public Health Emergency: SOLIDARITY TRIAL PhilippinesCompletedNCT05024006Not applicable
- Acalabrutinib and Rituximab in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT05004064Phase 2
- Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyActive, not recruitingNCT04978584Phase 2
- Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and LeukemiaWithdrawnNCT04961801Phase 1/2
- A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196CompletedNCT04914936Phase 1
- Acalabrutinib in CNSLActive, not recruitingNCT04906902Phase 1/2
- A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult ParticipantsCompletedNCT04905043Phase 1
- A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy ParticipantsCompletedNCT04901923Phase 1
- A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult ParticipantsCompletedNCT04898101Phase 1
- Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLLCompletedNCT04883749Phase 2
- A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With OmeprazoleCompletedNCT04876807Phase 1
- A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult ParticipantsCompletedNCT04867980Phase 1
- A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196CompletedNCT04867941Phase 1
- Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaWithdrawnNCT04836832Phase 1
- Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib CapsuleCompletedNCT04768985Phase 1
- Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04765111Phase 2
- A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLLActive, not recruitingNCT04722172Phase 2
- Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLLWithdrawnNCT04685915Phase 2
- Early Intervention With Acalabrutinib in Patients With High Risk CLLWithdrawnNCT04660045Phase 2
- World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 TreatmentsStatus unknownNCT04647669Phase 3
- Study of Acalabrutinib and Tafasitamab in MZL PatientsActive, not recruitingNCT04646395Phase 2
- Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaActive, not recruitingNCT04624906Phase 2